The phase III APOLLO trial demonstrates that arsenic trioxide combined with all-trans retinoic acid (ATRA) plus low-dose idarubicin improves event-free survival and reduces relapse rates compared to standard ATRA plus anthracycline chemotherapy in high-risk APL patients, with fewer serious adverse events.